High-Dose Toremifene as a Promising Candidate Therapy for Hormone Receptor-Positive Metastatic Breast Cancer with Secondary Resistance to Aromatase Inhibitors

There are currently no established second- and later-line therapies for postmenopausal women with hormone receptor-positive advanced or metastatic breast cancer. We examined the efficacy of high-dose toremifene (HD-TOR) for this patient group and whether aromatase inhibitor (AI) resistance influence...

Descripción completa

Detalles Bibliográficos
Autores principales: Fushimi, Atsushi, Tabei, Isao, Fuke, Azusa, Okamoto, Tomoyoshi, Takeyama, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7037483/
https://www.ncbi.nlm.nih.gov/pubmed/32099680
http://dx.doi.org/10.1155/2020/7156574

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7037483/
https://www.ncbi.nlm.nih.gov/pubmed/32099680
http://dx.doi.org/10.1155/2020/7156574

Ejemplares similares